UNAIDS estimated that there were some ******* people worldwide that died from acquired immune deficiency syndrome (AIDS) in 2024. This statistic depicts the total number of annual AIDS-related deaths worldwide from 2000 to 2024. HIV/AIDS burden A majority of countries with the highest burden due to HIV and AIDS are in Africa- in 2024, the highest number of AIDS-related deaths occurred in South Africa and Mozambique and the highest prevalence of HIV was found in Eswatini. Although access to life-saving antiretroviral therapy treatment (ART) has increased globally over recent years, many individuals living with HIV still lack access to ART. Barriers and interventions In part due to the development of ART, the number of people living with HIV worldwide is continuing to increase, reaching almost ** million in 2024. Important public health measures to combat the burden of the disease include a combination of biomedical and behavioral interventions such as pre- and post-exposure prophylaxis, and context-specific structural interventions to reduce barriers to supplies and education. One prominent barrier faced by those living with HIV is stigma, which can often cause disadvantages in many areas of life, including employment, use of health services, and social support.

In 2024, South Africa and Mozambique had the highest number of deaths due to AIDS worldwide, with around ** thousand and ** thousand such deaths, respectively. African countries account for eight of the top 10 countries with the highest number of AIDS-related deaths worldwide. AIDS-related deaths worldwide have been gradually declining over the past decade, decreasing from *** million deaths in 2010 to *** thousand deaths in 2024. HIV/AIDS HIV (human immunodeficiency virus) is an infectious sexually transmitted disease that is transmitted via exposure to infected semen, blood, vaginal and anal fluids and breast milk. HIV weakens the human immune system, resulting in the affected person being unable to fight off opportunistic infections. The top 15 countries worldwide with the highest prevalence of new HIV infections as of 2024 were all African. HIV treatment Although there is currently no effective cure for HIV, death can be prevented by taking HIV antiretroviral therapy (ART). Access to antiretroviral therapy worldwide has significantly increased in the past decade. As of 2024, around **** million people with HIV worldwide were receiving ART. The countries with the highest percentage of HIV-infected children who were receiving ART were Eswatini, Kenya, and Lesotho.

Dataset Overview

The dataset provides a comprehensive look at HIV/AIDS adult prevalence rates, the number of people living with HIV, and annual deaths across different countries. It is based on publicly available data sources such as the CIA World Factbook, UNAIDS AIDS Info, and other global health organizations. The dataset primarily focuses on adult HIV prevalence (ages 15–49) and includes estimates from recent years (e.g., 2023–2024).

Data Science Applications

This dataset can be used for: - Epidemiological Analysis: Understanding the regional distribution of HIV/AIDS and identifying high-prevalence areas. - Predictive Modeling: Developing machine learning models to predict HIV prevalence trends or identify risk factors. - Resource Allocation: Informing policymakers about regions requiring urgent intervention or resource allocation. - Health Outcome Monitoring: Tracking progress in combating HIV/AIDS over time. - Social Determinants Research: Analyzing the relationship between socio-economic factors and HIV prevalence.

Column Descriptors

1. Country/Region: The geographical area being analyzed.
2. Adult Prevalence (%): Percentage of adults aged 15–49 living with HIV.
3. Number of People with HIV/AIDS: Absolute count of individuals living with HIV in the region.
4. Annual Deaths from HIV/AIDS: Number of deaths attributed to HIV/AIDS annually.
5. Year of Estimate: The year when the data was collected or estimated.

Ethically Mined Data

The dataset is ethically sourced from publicly available and credible platforms such as the CIA World Factbook, UNAIDS, and WHO. These organizations ensure transparency and ethical standards in data collection, protecting individual privacy while providing aggregate statistics for research purposes.

Acknowledgments

1. Data Source Platforms:
   • CIA World Factbook
   • UNAIDS AIDS Info
   • WHO Global Health Observatory
2. Dataset Visualization Image:
   • Created using DALL-E 3 for illustrative purposes.
3. Research Support:
   • Contributions from platforms like ResearchGate, NIMH, and others for insights into data science applications in HIV research.

This dataset serves as a valuable tool for researchers, policymakers, and public health professionals in addressing the global challenge of HIV/AIDS.

In January 2025, President Trump ordered a pause on funding for the U.S. Agency for International Development (USAID) and a 90-day review of all U.S. foreign assistance. By the end of March, the review had been completed, 83 percent of USAID programs were terminated, and it was announced that certain USAID functions would be overtaken by the Department of State while all others would be discontinued. A preprint research paper posted in April 2025 looked at the possible effects that reductions or cessation of U.S. foreign aid would have on global health. The researchers estimated that the elimination of U.S. foreign aid for global health would result in an additional 15.2 million AIDS-related deaths from 2025 to 2040. Furthermore, they estimated that the loss of U.S. aid would lead to 26.2 million additional HIV infections over this period. This paper has not been peer-reviewed so the estimates should be interpreted with caution, but there is no doubt that such cuts to U.S. foreign aid will result in an increase in HIV infections and deaths, especially in high-impact countries. Trump has said that the United States spends too much on foreign aid and accused USAID of being corrupt and a waste of money. However, foreign aid accounts for just one percent of the federal budget. Furthermore, it is predicted that millions of people will die due to the dissolution of USAID, as vulnerable people around the world will no longer be able to access prevention and treatment for diseases such as HIV/AIDS, tuberculosis, and malaria.

this graph was created in Tableu and Ourdataworld :

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2Fc5bb0b21c8b3a126eca89160e1d25d03%2Fgraph1.png?generation=1710708871099084&alt=media" alt="">

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2Ff81fcfa72e97f08202ba1cb06fe138da%2Fgraph2.png?generation=1710708877558039&alt=media" alt="">

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2Fabbdfd146844a7e8d19e277c2eecb83b%2Fgraph3.png?generation=1710708883608541&alt=media" alt="">

Understanding the Global Distribution of HIV/AIDS Deaths

Introduction:

HIV/AIDS remains one of the most significant public health challenges globally, with its impact varying widely across countries and regions. While the overall share of deaths attributed to HIV/AIDS stands at around 1.5% globally, this statistic belies the stark disparities observed on a country-by-country basis. This essay delves into the global distribution of deaths from HIV/AIDS, examining both the overarching trends and the localized impacts across different regions, particularly focusing on Southern Sub-Saharan Africa.

Understanding Global Trends:

At a global level, HIV/AIDS accounts for approximately 1.5% of all deaths. This figure, though relatively low in comparison to other causes of mortality, represents a significant burden on public health systems and communities worldwide. However, when zooming in on specific regions, such as Europe, the share of deaths attributable to HIV/AIDS drops significantly, often comprising less than 0.1% of total mortality. This pattern suggests varying levels of prevalence and effectiveness of HIV/AIDS prevention and treatment strategies across different parts of the world.

Regional Disparities:

The distribution of HIV/AIDS deaths is not uniform across the globe, with certain regions experiencing disproportionately high burdens. Southern Sub-Saharan Africa emerges as a focal point of the HIV/AIDS epidemic, with a significant portion of deaths attributed to the virus occurring in this region. Factors such as limited access to healthcare, socio-economic disparities, cultural stigmatization, and insufficient education about HIV/AIDS contribute to the heightened prevalence and impact of the disease in this area.

Southern Sub-Saharan Africa: A Hotspot for HIV/AIDS Deaths:

Within Southern Sub-Saharan Africa, countries such as South Africa, Botswana, and Swaziland stand out for their exceptionally high rates of HIV/AIDS-related mortality. In these nations, HIV/AIDS can account for up to a quarter of all deaths, highlighting the acute nature of the epidemic in these regions. The reasons behind this disproportionate burden are multifaceted, encompassing issues ranging from inadequate healthcare infrastructure to socio-cultural barriers inhibiting prevention and treatment efforts.

Challenges and Responses:

Addressing the unequal distribution of HIV/AIDS deaths necessitates a multi-faceted approach that encompasses both prevention and treatment strategies tailored to the specific needs of affected communities. Efforts to expand access to antiretroviral therapy (ART), promote comprehensive sexual education, combat stigma, and strengthen healthcare systems are crucial components of an effective response. Moreover, fostering partnerships between governments, civil society organizations, and international entities is essential for coordinating resources and expertise to tackle the HIV/AIDS epidemic comprehensively.

Lessons Learned and Future Directions:

The global distribution of deaths from HIV/AIDS underscores the importance of context-specific interventions that take into account the unique social, economic, and cultural factors influencing the spread and impact of the disease. While progress has been made in reducing HIV/AIDS-related mortality in some regions, much work remains to be done, particularly in areas where the burden of the epidemic remains disproportionately high. Going forward, sustained investment in research, healthcare infrastructure, and community empowerment initiatives will be vital for achieving meaningful reductions in HIV/AIDS deaths worldwide.

Conclusion:

In conclusion, the global distribution of deaths from HIV/AIDS reveals a complex landscape characterized by both overarching trends and localized disparities. While the overall share of deaths attributable to HIV/AIDS may seem relatively modest on a global scale, the stark contrasts observed across different countries and regions underscore the need for targeted interventions tailored to the specific contexts in which the epidemic is most pronounced. By addressing the underlying social, economic, and healthcare-related factors driving the unequal distribution of HIV/AIDS deaths, the global co...

Introduction

• HIV (human immunodeficiency virus) is a virus that attacks the body's immune system. If HIV is not treated, it can lead to AIDS (acquired immunodeficiency syndrome) which currently has no cure. Once people get HIV, they have it for life. But with proper medical care, HIV can be controlled. Symptoms: Influenza-like illness; Fatigue… Treatments: Management of HIV/AIDS Type of infectious agent: Virus (Human Immunodeficiency Virus) • AIDS (acquired immune deficiency syndrome) is the name used to describe a number of potentially life-threatening infections and illnesses that happen when one’s immune system has been severely damaged by the HIV virus. While AIDS cannot be transmitted from 1 person to another, the HIV virus can.

Dataset

The data set contains data of the following:- 1. The top causes of deaths in the world 2. Total number of deaths due to HIV/AIDS 3. ART (Anti Retro-viral Therapy) coverage among people living with HIV 4. Knowledge among young citizens (15-24years) about HIV/AIDS 5. Population of HIV/AIDS patients living with TB and their death rate 6. Life expectancy rate among HIV/AIDS patients 7. HIV/AIDS Patients in different age groups 8. Women population living with HIV 9. Young women in India having the knowledge of HIV/AIDS 10. HIV/AIDS deaths in Indian states

Data was scrapped from the official website of UNICEF -https://data.unicef.org/ and https://data.gov.in/

Ask Phase

• Data gives the trend of increasing no. of HIV/AIDS patients across the world • The information available for each country is percentage of total Global AIDS patients • Time period traced is 2000-2019 • Key Questions to answer:  Which countries and regions are affected the most?  How are the different age groups affected?  How much is the ART (Anti Retro-viral Therapy) coverage among the patients and what is the life expectancy rate?  What percentage of the population is aware of the prevention and causes of HIV/AIDS

Prepare phase.

• By tabulating and filtering the data the required data was obtained to bring out observations. • Data was formatted to the desired format to perform further calculations. • Sorting of data region wise. • Columns with inconsistent and empty cells were deleted. • The data of India was extracted for further analysis • Duplicate entries and undesired data was removed

Process phase

For cleaning the dataset for further analysis MS Excel was used due to small data. • Used sumifs() functions to aggregate the data region wise • Used sumif() to segregate the no. of patients within different age groups • Used sumifs() to find the total number of TB patients among HIV deaths. • Used countif() to find the percentage of male and female patients. • Sorted data to find the top and bottom nation with most and least HIV/AIDS patients

Analyze phase

• Formed the following pivot tables to answer key target questions  Year v/s number of death rates  Country v/s death numbers to bring out nation wise deaths  Causes of death v/s the number of deaths to bring at which position AIDS causes causality  Year v/s percentage of life expectancy to observe the pattern of no. of survivors

Visualization phase

The data was visualized using Tableau.

Presentaion

The final presentation was prepared by accumulating all observations and inferences which is linked below https://docs.google.com/presentation/d/1NEX10Vz5u5Va3CrTLVbvsUHZjO-fn8EOeiOHkP03T3Q/edit?usp=sharing

As of 2024, South Africa was the country with the highest number of people living with HIV in Africa. At that time, around 7.8 million people in South Africa were HIV positive. In Mozambique, the country with the second-highest number of HIV-positive people in Africa, around 2.5 million people were living with HIV. Which country in Africa has the highest prevalence of HIV? Although South Africa has the highest total number of people living with HIV in Africa, it does not have the highest prevalence of HIV on the continent. Eswatini currently has the highest prevalence of HIV in Africa and worldwide, with almost 26 percent of the population living with HIV. South Africa has the third-highest prevalence, with around 18 percent of the population HIV positive. Eswatini also has the highest rate of new HIV infections per 1,000 population worldwide, followed by South Africa and Mozambique. However, South Africa had the highest total number of new HIV infections in 2024, with around 170,000 people newly infected with HIV that year. Deaths from HIV in Africa Thanks to advances in treatment and awareness, HIV/AIDS no longer contributes to a significant amount of death in many countries. However, the disease is still the eighth leading cause of death in Africa, accounting for around 4.6 percent of all deaths. In 2024, South Africa and Mozambique were the countries with the highest number of AIDS-related deaths worldwide, with 53,000 and 44,000 such deaths, respectively. Although not every country in the leading 25 for AIDS-related deaths is found in Africa, African countries account for the majority of countries on the list. Fortunately, HIV treatment has become more accessible in Africa over the years, and now up to 94 percent of people living with HIV in Eswatini are receiving antiretroviral therapy (ART). Access to ART does vary from country to country, however, with around 81 percent of people who are HIV positive in South Africa receiving ART and only 34 percent in the Congo.

Among all countries worldwide those in sub-Saharan Africa have the highest rates of HIV. The countries with the highest rates of HIV include Eswatini, South Africa, and Lesotho. In 2024, Eswatini had the highest prevalence of HIV with a rate of around ** percent. Other countries, such as Zimbabwe, have significantly decreased their HIV prevalence. Community-based HIV services are considered crucial to the prevention and treatment of HIV. HIV Worldwide The human immunodeficiency virus (HIV) is a viral infection that is transmitted via exposure to infected semen, blood, vaginal and anal fluids, and breast milk. HIV destroys the human immune system, rendering the host unable to fight off secondary infections. Globally, the number of people living with HIV has generally increased over the past two decades. However, the number of HIV-related deaths has decreased significantly in recent years. Despite being a serious illness that affects millions of people, medication exists that effectively manages the progression of the virus in the body. These medications are called antiretroviral drugs. HIV Treatment Generally, global access to antiretroviral treatment has increased. However, despite being available worldwide, not all adults have access to antiretroviral drugs. There are many different antiretroviral drugs available on the market. As of 2024, ********, an antiretroviral marketed by Gilead, was the leading HIV treatment based on revenue.

No. of Deaths: Caused by: HIV Disease (Aids) data was reported at 547.000 Person in Sep 2024. This records a decrease from the previous number of 557.000 Person for Jun 2024. No. of Deaths: Caused by: HIV Disease (Aids) data is updated quarterly, averaging 558.000 Person from Mar 2017 (Median) to Sep 2024, with 30 observations. The data reached an all-time high of 659.000 Person in Mar 2018 and a record low of 461.000 Person in Sep 2020. No. of Deaths: Caused by: HIV Disease (Aids) data remains active status in CEIC and is reported by National Administrative Department of Statistics. The data is categorized under Global Database’s Colombia – Table CO.G012: Number of Deaths: Cause of Death.

BackgroundSince the first HIV/AIDS case appeared in 1980s, HIV/AIDS has been the focus of international attention. As a major public health problem, there are epidemiological uncertainties about the future of HIV/AIDS. It is important to monitor the global statistics of HIV/AIDS prevalence, deaths, disability adjusted life years (DALYs), and risk factors for adequate prevention and control.MethodsThe Global Burden of Disease Study 2019 database was used to analyze the burden of HIV/AIDS in 1990–2019. By extracting global, regional, and national data on HIV/AIDS prevalence, deaths, and DALYs, we described the distribution by age and sex, explored the risk factors, and analyzed the trends in HIV/AIDS.ResultsIn 2019, there were 36.85 million HIV/AIDS cases (95% UI: 35.15–38.86 million), 863.84 thousand deaths (95% UI: 78.61–99.60 thousand), and 47.63 million (95% UI: 42.63–55.65 million) DALYs. The global age-standardized HIV/AIDS prevalence, death, and DALY rates were 454.32 (95% UI: 433.76–478.59), 10.72 (95% UI: 9.70–12.39), and 601.49 (95% UI: 536.16–703.92) per 100,000 cases, respectively. In 2019, the global age-standardized HIV/AIDS prevalence, death, and DALY rates increased by 307.26 (95% UI: 304.45–312.63), 4.34 (95% UI: 3.78–4.90), and 221.91 (95% UI: 204.36–239.47) per 100,000 cases, respectively, compared to 1990. Age-standardized prevalence, death, and DALY rates decreased in high sociodemographic index (SDI) areas. High age-standardized rates were observed in low sociodemographic index areas, while low age-standardized rates were observed in high sociodemographic index areas. In 2019, the high age-standardized prevalence, death, and DALY rates were predominant in Southern Sub-Saharan Africa, and global DALYs peaked in 2004 and subsequently decreased. The highest global HIV/AIDS DALYs were in the 40–44 age group. The main risk factors affecting HIV/AIDS DALY rates included behavioral risks, drug use, partner violence, and unsafe sex.ConclusionsHIV/AIDS disease burden and risk factors vary by region, sex, and age. As access to health care increases across countries and treatment for HIV/AIDS infection improves, the HIV/AIDS disease burden is concentrated in areas with low SDIs, particularly in South Africa. Regional differences should be fully considered to target optimal prevention strategies and treatment options based on risk factors.

2014 data provided by the World Health Organisation

HIV/AIDS deaths in the U.S. have dropped significantly in recent years. In 1995, the death rate from HIV per 100,000 people was ****. That number has since decreased to *** per 100,000 as of 2023. The reduction in the HIV death rate in the U.S. can be attributed to an increase in access to HIV medications. HIV/AIDS in the U.S. Human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) cause a systemic viral infection that damages the immune system. AIDS is a syndrome that is caused by HIV. AIDS is when the immune system is severely weakened by HIV and the body can no longer fight off infections. Among all U.S. states, Georgia, followed by Florida and Louisiana, had the highest rates of new HIV diagnoses in 2022. HIV/AIDS treatments in the U.S. HIV/AIDS treatments include antiretroviral medications to reduce the levels of HIV within the body. The largest funders for HIV/AIDS medications and research are the National Institutes of Health (NIH) and the Ryan White Program. The top HIV drug worldwide, based on revenue generated in 2023 was Biktarvy. Around the world, access to antiretroviral treatment has increased dramatically in recent years, a huge step in reducing the number of HIV-related deaths. There is currently no cure for HIV.

Abstract

The 2005 Vietnam Population and AIDS Indicator Survey (VPAIS) was designed with the objective of obtaining national and sub-national information about program indicators of knowledge, attitudes and sexual behavior related to HIV/AIDS. Data collection took place from 17 September 2005 until mid-December 2005.

The VPAIS was implemented by the General Statistical Office (GSO) in collaboration with the National Institute of Hygiene and Epidemiology (NIHE). ORC Macro provided financial and technical assistance for the survey through the USAID-funded MEASURE DHS program. Financial support was provided by the Government of Vietnam, the United States President’s Emergency Plan for AIDS Relief, the United States Agency for International Development (USAID), and the United States Centers for Disease Control and Prevention/Global AIDS Program (CDC/GAP).

The survey obtained information on sexual behavior, and knowledge, attitudes, and behavior regarding HIV/AIDS. In addition, in Hai Phong province, the survey also collected blood samples from survey respondents in order to estimate the prevalence of HIV. The overall goal of the survey was to provide program managers and policymakers involved in HIV/AIDS programs with strategic information needed to effectively plan, implement and evaluate future interventions.

The information is also intended to assist policymakers and program implementers to monitor and evaluate existing programs and to design new strategies for combating the HIV/AIDS epidemic in Vietnam. The survey data will also be used to calculate indicators developed by the United Nations General Assembly Special Session on HIV/AIDS (UNGASS), UNAIDS, WHO, USAID, the United States President’s Emergency Plan for AIDS Relief, and the HIV/AIDS National Response.

The specific objectives of the 2005 VPAIS were: • to obtain information on sexual behavior. • to obtain accurate information on behavioral indicators related to HIV/AIDS and other sexually transmitted infections. • to obtain accurate information on HIV/AIDS program indicators. • to obtain accurate estimates of the magnitude and variation in HIV prevalence in Hai Phong Province.

Geographic coverage

National coverage

Analysis unit

• Household
• Women age 15-49
• Men age 15-49

Kind of data

Sample survey data [ssd]

Sampling procedure

The sampling frame for the 2005 Vietnam Population and AIDS Indicator Survey (VPAIS) was the master sample used by the General Statistical Office (GSO) for its annual Population Change Survey (PCS 2005). The master sample itself was constructed in 2004 from the 1999 Population and Housing Census. As was true for the VNDHS 1997 and the VNDHS 2002 the VPAIS 2005 is a nationally representative sample of the entire population of Vietnam.

The survey utilized a two-stage sample design. In the first stage, 251 clusters were selected from the master sample. In the second stage, a fixed number of households were systematically selected within each cluster, 22 households in urban areas and 28 in rural areas.

The total sample of 251 clusters is comprised of 97 urban and 154 rural clusters. HIV/AIDS programs have focused efforts in the four provinces of Hai Phong, Ha Noi, Quang Ninh and Ho Chi Minh City; therefore, it was determined that the sample should be selected to allow for representative estimates of these four provinces in addition to the national estimates. The selected clusters were allocated as follows: 35 clusters in Hai Phong province where blood samples were collected to estimate HIV prevalence; 22 clusters in each of the other three targeted provinces of Ha Noi, Quang Ninh and Ho Chi Minh City; and the remaining 150 clusters from the other 60 provinces throughout the country.

Prior to the VPAIS fieldwork, GSO conducted a listing operation in each of the selected clusters. All households residing in the sample points were systematically listed by teams of enumerators, using listing forms specially designed for this activity, and also drew sketch maps of each cluster. A total of 6,446 households were selected. The VPAIS collected data representative of: • the entire country, at the national level • for urban and rural areas • for three regions (North, Central and South), see Appendix for classification of regions. • for four target provinces: Ha Noi, Hai Phong, Quang Ninh and Ho Chi Minh City.

All women and men aged 15-49 years who were either permanent residents of the sampled households or visitors present in the household during the night before the survey were eligible to be interviewed in the survey. All women and men in the sample points of Hai Phong who were interviewed were asked to voluntarily give a blood sample for HIV testing. For youths aged 15-17, blood samples were drawn only after first obtaining consent from their parents or guardians.

(Refer Appendix A of the final survey report for details of sample implementation)

Mode of data collection

Face-to-face [f2f]

Research instrument

Two questionnaires were used in the survey, the Household Questionnaire and the Individual Questionnaire for women and men aged 15-49. The content of these questionnaires was based on the model AIDS Indicator Survey (AIS) questionnaires developed by the MEASURE DHS program implemented by ORC Macro.

In consultation with government agencies and local and international organizations, the GSO and NIHE modified the model questionnaires to reflect issues in HIV/AIDS relevant to Vietnam. These questionnaires were then translated from English into Vietnamese. The questionnaires were further refined after the pretest.

The Household Questionnaire was used to list all the usual members and visitors in the selected households. Some basic information was collected on the characteristics of each person listed, including age, sex, relationship to the head of the household, education, basic material needs, survivorship and residence of biological parents of children under the age of 18 years and birth registration of children under the age of 5 years. The main purpose of the Household Questionnaire was to identify women and men who were eligible for the individual interview. The Household Questionnaire also collected information on characteristics of the household’s dwelling unit, such as the source of drinking water, type of toilet facilities, type of material used in the flooring of the house, and ownership of various durable goods, in order to allow for the calculation of a wealth index. The Household Questionnaire also collected information regarding ownership and use of mosquito nets.

The Individual Questionnaire was used to collect information from all women and men aged 15-49 years.

All questionnaires were administered in a face-to-face interview. Because cultural norms in Vietnam restrict open discussion of sexual behavior, there is concern that this technique may contribute to potential under-reporting of sexual activity, especially outside of marriage.

All aspects of VPAIS data collection were pre-tested in July 2005. In total, 24 interviewers (12 men and 12 women) were involved in this task. They were trained for thirteen days (including three days of fieldwork practice) and then proceeded to conduct the survey in the various urban and rural districts of Ha Noi. In total, 240 individual interviews were completed during the pretest. The lessons learnt from the pretest were used to finalize the survey instruments and logistical arrangements for the survey and blood collection.

Cleaning operations

The data processing of the VPAIS questionnaire began shortly after the fieldwork commenced. The first stage of data editing was done by the field editors, who checked the questionnaires for completeness and consistency. Supervisors also reviewed the questionnaires in the field. The completed questionnaires were then sent periodically to the GSO in Ha Noi by mail for data processing.

The office editing staff first checked that questionnaires of all households and eligible respondents had been received from the field. The data were then entered and edited using CSPro, a software package developed collaboratively between the U.S. Census Bureau, ORC Macro, and SerPRO to process complex surveys. All data were entered twice (100 percent verification). The concurrent processing of the data was a distinct advantage for data quality, as VPAIS staff was able to advise field teams of errors detected during data entry. The data entry and editing phases of the survey were completed by the end of December 2005.

Response rate

A total of 6,446 households were selected in the sample, of which 6,346 (98 percent) were found to be occupied at the time of the fieldwork. Occupied households include dwellings in which the household was present but no competent respondent was home, the household was present but refused the interview, and dwellings that were not found. Of occupied households, 6,337 were interviewed, yielding a household response rate close to 100 percent.

All women and men aged 15-49 years who were either permanent residents of the sampled households or visitors present in the household during the night before the survey were eligible to be interviewed in the survey. Within interviewed households, a total of 7,369 women aged 15-49 were identified as eligible for interview, of whom 7,289 were interviewed, yielding a response rate to the Individual interview of 99 percent among women. The high response rate was also achieved in male interviews. Among the 6,788 men aged 15-49 identified as eligible for interview, 6,707 were successfully interviewed, yielding a response rate of 99 percent.

Sampling error

This dataset provides detailed insights into the prevalence of HIV/AIDS among adults (ages 15–49) across various countries and regions. The data is primarily sourced from the CIA World Factbook and the UNAIDS AIDSinfo platform and reflects the most recent available estimates as of 2022–2024.

What’s Included:

Country/Region – The name of each nation or area.

Adult Prevalence of HIV/AIDS (%) – The percentage of adults estimated to be living with HIV.

Number of People with HIV/AIDS – Estimated count of people infected in each country.

Annual Deaths from HIV/AIDS – Estimated number of HIV/AIDS-related deaths per year.

Year of Estimate – The year the data was reported or estimated.

Key Highlights:

Global Prevalence: Around 0.7% of the global population was living with HIV in 2022, affecting nearly 39 million people.

Hotspots: The epidemic is most severe in Southern Africa, with countries like Eswatini, Botswana, Lesotho, and Zimbabwe reporting adult prevalence rates above 20%.

High Burden Countries:

South Africa: 17.3% prevalence, approximately 9.2 million infected

Tanzania: approximately 7.49 million

Mozambique: approximately 2.48 million

Nigeria: approximately 2.45 million (1.3% prevalence)

Notes:

Data may vary in accuracy and is subject to ongoing updates and verification.

Some entries include a dash ("-") where data was not published or available.

Countries with over 1% adult prevalence are categorized under Generalized HIV Epidemics (GHEs) by UNAIDS.

BackgroundThrough major efforts to reduce costs and expand access to antiretroviral therapy worldwide, widespread delivery of effective treatment to people living with HIV/AIDS is now conceivable even in severely resource-constrained settings. However, the potential epidemiologic impact of treatment in the context of a broader strategy for HIV/AIDS control has not yet been examined. In this paper, we quantify the opportunities and potential risks of large-scale treatment roll-out. Methods and FindingsWe used an epidemiologic model of HIV/AIDS, calibrated to sub-Saharan Africa, to investigate a range of possible positive and negative health outcomes under alternative scenarios that reflect varying implementation of prevention and treatment. In baseline projections, reflecting “business as usual,” the numbers of new infections and AIDS deaths are expected to continue rising. In two scenarios representing treatment-centered strategies, with different assumptions about the impact of treatment on transmissibility and behavior, the change in the total number of new infections through 2020 ranges from a 10% increase to a 6% reduction, while the number of AIDS deaths through 2020 declines by 9% to 13%. A prevention-centered strategy provides greater reductions in incidence (36%) and mortality reductions similar to those of the treatment-centered scenarios by 2020, but more modest mortality benefits over the next 5 to 10 years. If treatment enhances prevention in a combined response, the expected benefits are substantial—29 million averted infections (55%) and 10 million averted deaths (27%) through the year 2020. However, if a narrow focus on treatment scale-up leads to reduced effectiveness of prevention efforts, the benefits of a combined response are considerably smaller—9 million averted infections (17%) and 6 million averted deaths (16%). Combining treatment with effective prevention efforts could reduce the resource needs for treatment dramatically in the long term. In the various scenarios the numbers of people being treated in 2020 ranges from 9.2 million in a treatment-only scenario with mixed effects, to 4.2 million in a combined response scenario with positive treatment–prevention synergies. ConclusionsThese analyses demonstrate the importance of integrating expanded care activities with prevention activities if there are to be long-term reductions in the number of new HIV infections and significant declines in AIDS mortality. Treatment can enable more effective prevention, and prevention makes treatment affordable. Sustained progress in the global fight against HIV/AIDS will be attained only through a comprehensive response.

According to Cognitive Market Research, the global HIV Diagnostics market size is USD 4158.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 10.90% from 2024 to 2031. North America held the major market share for more than 40% of the global revenue with a market size of USD 1663.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031. Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1247.46 million. Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 956.39 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.9% from 2024 to 2031. Latin America had a market share of more than 5% of the global revenue with a market size of USD 207.91 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.3% from 2024 to 2031. Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 83.16 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.6% from 2024 to 2031. Consumables held the highest HIV Diagnostics market revenue share in 2024. Market Dynamics of HIV Diagnostics Market Key Drivers for HIV Diagnostics Market Increasing Prevalence of Sexually Transmitted Disease to Increase the Demand Globally Throughout the many decades of the HIV pandemic, the number of infected individuals is continually rising. The socioeconomic variables driving this continuous increase also suggest that preventative measures have not been successful. Even though many of these infections are preventable, there are an estimated 20 million new cases of STDs in the US each year, and the rate is still rising. Moreover, there are over 1.2 million HIV-positive individuals residing in the United States. Attempts to encourage testing and screening for sexually transmitted infections can ascertain an individual's likelihood of acquiring one and help those who already have one receive treatment, so enhancing their health and lowering the danger of HIV spreading to others. Approximately 38.4 million people worldwide were HIV positive in 2021. Among these, women and girls made up nearly 54%. Rising Initiatives by Global Agencies to Propel Market Growth HIV is among the world's most important public health concerns. As a result, there is a global commitment to stopping new HIV infections and giving everyone on the planet access to HIV therapy. WHO recommends testing for HIV to anyone who might be at risk. The World Bank was a leader in global financing for HIV/AIDS in the early phases of the pandemic and has contributed US$4.6 billion to programs related to the illness since 1989. Because of assistance from the Bank—more precisely, through the International Development Association—for 1,500 counseling and testing centers, about 7 million people have had HIV tests. Restraint Factor for the HIV Diagnostics Market Lack of Healthcare Infrastructure and Awareness to Limit the Sales A proper infrastructure for healthcare delivery is lacking in many areas, especially in poor nations, which makes it difficult to provide diagnostic services. This covers concerns with the supply chain, inadequate laboratory facilities, and skilled staff. It might be particularly difficult to access diagnostic services in rural and isolated places due to a lack of healthcare facilities and inadequate transportation infrastructure. Furthermore, HIV diagnosis rates are lower in the developing Asia-Pacific, Middle East, and African regions. These areas require a sufficient number of diagnostic facilities. Additionally, the diagnosis process needs to be explained to the majority of patients, which restricts market growth in these areas. Impact of Covid-19 on the HIV Diagnostics Market The COVID-19 pandemic has had a significant impact on the HIV diagnostics market, both in terms of challenges and opportunities. There was a decrease in HIV testing and diagnostic services during the pandemic as a result of the extensive healthcare resources being redirected to handle COVID-19. Some facilities were converted to provide COVID-19 treatment, and clinics and labs had a staffing crisis. Reduced HIV testing rates were the outcome of routine and community-based HIV testing programs being frequently halted to stop the spread of COVID-19. The adoption of telemedicine and remote healthcare services was expedited by the epidem...

This statistic describes some of the key figures on the global HIV/AIDS epidemic as of 2024. For 2024, it was estimated that there were a total of 40.8 million people living with HIV/AIDS around the world. Around 31.6 million of these people had access to antiretroviral therapy treatment.

Users can access data related to international women’s health as well as data on population and families, education, work, power and decision making, violence against women, poverty, and environment. Background World’s Women Reports are prepared by the Statistics Division of the United Nations Department for Economic and Social Affairs (UNDESA). Reports are produced in five year intervals and began in 1990. A major theme of the reports is comparing women’s situation globally to that of men in a variety of fields. Health data is available related to life expectancy, cause of death, chronic disease, HIV/AIDS, prenatal care, maternal morbidity, reproductive health, contraceptive use, induced abortion, mortality of children under 5, and immunization. User functionality Users can download full text or specific chapter versions of the reports in color and black and white. A limited number of graphs are available for download directly from the website. Topics include obesity and underweight children. Data Notes The report and data tables are available for download in PDF format. The next report is scheduled to be released in 2015. The most recent report was released in 2010.

HIV-1 Testing Market Outlook

The global HIV-1 testing market size was valued at approximately USD 2.5 billion in 2023 and is projected to reach USD 4.8 billion by 2032, exhibiting a CAGR of 7.2% over the forecast period. The market is primarily driven by the increasing prevalence of HIV/AIDS worldwide, advancements in diagnostic technologies, and growing awareness about early diagnosis and treatment. The significant rise in the number of government initiatives and funding aimed at combating HIV/AIDS is also expected to propel the market growth.

One of the key growth factors in the HIV-1 testing market is the continuous increase in HIV prevalence globally. According to UNAIDS, around 37.7 million people were living with HIV worldwide in 2020. This substantial patient pool necessitates the need for effective and accessible diagnostic tools. Governments and healthcare organizations are increasingly investing in initiatives to enhance HIV testing services, which in turn is expected to drive market growth. Additionally, the growing awareness and educational campaigns about HIV/AIDS and its early detection are contributing to the increased adoption of HIV-1 testing.

Technological advancements in diagnostic tools represent another crucial driver for the HIV-1 testing market. The development of highly sensitive and specific tests, such as nucleic acid tests (NAT) and fourth-generation antigen/antibody combination assays, has significantly improved the accuracy and reliability of HIV diagnosis. These advanced testing methods can detect the virus at an earlier stage, thereby facilitating timely intervention and treatment. The integration of point-of-care testing (POCT) devices has further enhanced the accessibility and convenience of HIV testing, particularly in resource-limited settings.

The increase in government initiatives and funding directed towards HIV/AIDS research and prevention is also playing a pivotal role in the market's growth. Various international agencies and governments are actively involved in efforts to reduce the transmission of HIV and improve the quality of life for those affected. For instance, the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis, and Malaria are significant contributors in this domain. These initiatives are not only focused on providing antiretroviral treatments but also emphasize the importance of regular and early testing, thereby boosting the market for HIV-1 diagnostic tests.

Sleeping Sickness Testing is another critical area of focus in the realm of infectious disease diagnostics. Sleeping sickness, or Human African Trypanosomiasis, is a parasitic disease that poses significant health challenges in certain regions of Africa. The development and deployment of effective testing methods for sleeping sickness are crucial for early detection and treatment, which can prevent severe health complications and reduce mortality rates. Advances in diagnostic technologies, similar to those seen in the HIV-1 testing market, are being leveraged to improve the sensitivity and specificity of sleeping sickness tests. These innovations are vital for enhancing disease management and supporting global health initiatives aimed at eradicating neglected tropical diseases.

Regionally, North America holds a significant share in the HIV-1 testing market, driven by the high prevalence of HIV, advanced healthcare infrastructure, and robust government initiatives. Europe follows closely, with increasing awareness and improved healthcare facilities. The Asia Pacific region is expected to witness the fastest growth during the forecast period, fueled by rising HIV cases, increasing healthcare expenditure, and growing public health campaigns. Latin America and the Middle East & Africa are also anticipated to contribute to market growth, owing to the expanding healthcare services and international support for combating HIV/AIDS.

Test Type Analysis

The HIV-1 testing market can be segmented by test type into antibody tests, antigen tests, nucleic acid tests (NAT), and others. Antibody tests are among the most commonly used HIV diagnostic tools, primarily due to their high sensitivity and specificity. These tests detect antibodies produced by the body in response to HIV infection and are widely used in both clinical and non-clinical settings. The ease of use and cost-effectiveness of antibody tests make them a popular choice in resource-limited settings, contributing

Abstract

This 2011-12 Tanzania HIV/AIDS and Malaria Indicator Survey (THMIS) was implemented by the National Bureau of Statistics (NBS) in collaboration with the Office of the Chief Government Statistician (OCGS-Zanzibar) from December 16, 2011, to May 24, 2012.The Tanzania Commission for AIDS (TACAIDS) and the Zanzibar AIDS Commission authorized the National Bureau of Statistics (NBS) to conduct the 2011-12 THMIS. The survey covers both the Tanzania Mainland and Zanzibar.

The objectives of the 2011-12 THMIS were to collect data on knowledge and behaviour regarding HIV/AIDS and malaria, measure HIV prevalence among women and men age 15-49, and measure the presence of malaria parasites and anaemia among children age 6-59 months. The 2011-12 THMIS follows up on the 2007-08 THMIS and the 2003-04 Tanzania HIV/AIDS Indicator Survey (THIS). The 2011-12 THMIS also updates estimates of selected basic demographic and health indicators covered in previous surveys, including the 1991-92 Tanzania Demographic and Health Survey (TDHS), the 1996 TDHS, the 1999 Reproductive and Child Health Survey, the 2004-05 TDHS, and the 2010 TDHS.

Geographic coverage

National coverage

Analysis unit

• Individuals
• Households

Universe

The survey covered all de jure household members (usual residents), all eligible men and women aged between 15-49 years, and all children age 6-59 months in the household.

Kind of data

Sample survey data [ssd]

Sampling procedure

The sampling frame used for the 2011-12 THMIS was developed by the National Bureau of Statistics (NBS) after the 2002 Population and Housing Census (PHC) and is the same as that used for the 2010 and 2004-05 Tanzania Demographic and Health Surveys (TDHS), the 2007-2008 THMIS, and the 2003-04 Tanzania HIV and AIDS Indicator Survey (THIS). The sampling frame excluded nomadic and institutional populations such as persons in hotels, barracks, and prisons.

The 2011-12 THMIS was designed to allow estimates of key indicators for each of Tanzania's 30 regions. The sample was selected in two stages. The first stage involved selecting sample points (clusters) consisting of enumeration areas (EAs) delineated for the 2002 PHC. A total of 583 clusters were selected.On the Mainland, 30 sample points were selected in Dar es Salaam and 20 were selected in each of the other 24 regions.2 In Zanzibar, 15 sample points were selected in each of the five regions.

The second stage of selection involved the systemic sampling of households. A household listing operation was undertaken in all the selected areas prior to the fieldwork. From these lists, households to be included in the survey were selected. Approximately 18 households were selected from each sample point for a total sample size of 10,496 households.

The sampling procedures are more fully described in "Tanzania HIV/AIDS and Malaria Indicator Survey 2011-2012 - Final Report" pp.4-5.

Mode of data collection

Face-to-face [f2f]

Research instrument

Two questionnaires were used for the 2011-12 THMIS: the Household Questionnaire and the Individual Questionnaire. These questionnaires are based on the MEASURE DHS standard AIDS Indicator Survey and Malaria Indicator Survey questionnaires and were adapted to reflect the population and health issues relevant to Tanzania. Input was solicited from various stakeholders representing government ministries and agencies, nongovernmental organizations, development partners, and international donors. After the preparation of the definitive questionnaires in English, the questionnaires were translated into Kiswahili.

The Household Questionnaire was used to list all the usual members and visitors of selected households. Some basic demographic information was collected on the characteristics of each person, including his or her age, sex, education, and relationship to the head of the household. For children under age 18, survival status of the parents was determined. The data on age and sex of household members obtained in the Household Questionnaire was used to identify women and men who were eligible for the individual interview and HIV testing. The Household Questionnaire also collected information on characteristics of the household’s dwelling unit, such as the source of water, type of toilet facilities, materials used for the floor of the house, ownership of various durable goods, and ownership and use of mosquito nets. The Household Questionnaire was also used to record haemoglobin and malaria testing results for children age 6-59 months.

The Individual Questionnaire was used to collect information from all eligible women and men age 15-49. These respondents were asked questions on the following topics: - Background characteristics (education, media exposure, etc.) - Marriage and sexual activity - Employment - Awareness and behaviour regarding HIV/AIDS and other sexually transmitted infections (STIs) - Knowledge and awareness of malaria - Other health issues

Female respondents were asked to provide their birth history for the six years preceding the interview and information about recent fever and treatment of fever for children born since January 2006.

Response rate

A total of 10,496 households were selected for the sample, from both Mainland Tanzania and Zanzibar. Of these, 10,226 were found to be occupied at the time of the survey. A total of 10,040 households were successfully interviewed, yielding a response rate of 98 percent. In the interviewed households, 11,423 women were identified as eligible for the individual interview. Completed interviews were obtained for 10,967 women, yielding a response rate of 96 percent. Of the 9,388 eligible men identified, 8,352 were successfully interviewed (89 percent response rate).

The principal reason for nonresponse among both eligible women and men was the failure to find them at home despite repeated visits to the households. The lower response rate among men than among women was due to the more frequent and longer absences of men from the households.

Sampling error estimates

The estimates from a sample survey are affected by two types of errors: non-sampling errors and sampling errors. Non-sampling errors are the results of mistakes made in implementing data collection and data processing, such as failure to locate and interview the correct household, misunderstanding of the questions on the part of either the interviewer or the respondent, and data entry errors. Although numerous efforts were made during the implementation of the 2011-12 Tanzania HIV/AIDS and Malaria Indicator Survey (2011-12 THMIS) to minimize this type of error, non-sampling errors are impossible to avoid and difficult to evaluate statistically.

Sampling errors, on the other hand, can be evaluated statistically. The sample of respondents selected in the 2011-12 THMIS is only one of many samples that could have been selected from the same population, using the same design and expected size. Each of these samples would yield results that differ somewhat from the results of the actual sample selected. Sampling errors are a measure of the variability among all possible samples. Although the degree of variability is not known exactly, it can be estimated from the survey results.

Sampling error is usually measured in terms of the standard error for a particular statistic (mean, percentage, etc.), which is the square root of the variance. The standard error can be used to calculate confidence intervals within which the true value for the population can reasonably be assumed to fall. For example, for any given statistic calculated from a sample survey, the value of that statistic will fall within a range of plus or minus two times the standard error of that statistic in 95 percent of all possible samples of identical size and design.

If the sample of respondents had been selected as a simple random sample, it would have been possible to use straightforward formulas for calculating sampling errors. However, the 2011-12 THMIS sample is the result of a multi-stage stratified design, and, consequently, it was necessary to use more complex formulas. Sampling errors are computed by SAS, using programs developed by ICF International. These programs use the Taylor linearization method of variance estimation for survey estimates that are means, proportions, or ratios. The Jackknife repeated replication method is used for variance estimation of more complex statistics such as fertility and mortality rates.

The estimates of sampling error are more fully described in appendix B in document "Tanzania HIV/AIDS and Malaria Indicator Survey 2011-2012 - Final Report" pp.199-200.

Data appraisal

A series of data quality tables are available to review the quality of the data and include the following:

• Age distribution of the household population
• Age distribution of eligible and interviewed women
• Age distribution of eligible and interviewed men
• Completeness of reporting

The results of each of these data quality tables are shown in appendix C in document "Tanzania HIV/AIDS and Malaria Indicator Survey 2011-2012 - Final Report" pp.227-229.